Showing results (51-60 of 68) with videos related to
Sort By:
Pageof 7
Breast Cancer Research and Treatment|November 4, 2016
Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysisClémentine Jankowski, S Guiu, M Cortet, et al.European Journal of Cancer (Oxford, England : 1990)|April 20, 2012
Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11 years using propensity score matchingI Le Ray, S Dabakuyo, G Crehange, et al.British Journal of Cancer|January 13, 2006
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?L Arnould, M Gelly, F Penault-Llorca, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiformeC Twelves, M Campone, B Coudert, et al.European Journal of Cancer (Oxford, England : 1990)|October 26, 2001
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group reportB Coudert, A Anthoney, W Fiedler, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancerH Curé, V Chevalier, A Adenis, et al.The European Respiratory Journal|June 11, 2011
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3I Borget, J Cadranel, J-P Pignon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2001
Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patientsY Bécouarn, E Gamelin, B Coudert, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 30, 2012
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysisS Giacchetti, P A Dugué, P F Innominato, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2010
Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapyS Guiu, M Liegard, L Favier, et al.Pageof 7